



## XV. Follow-up schedule for nonseminoma stage I, surveillance

Name: \_\_\_\_\_ Civic registration number: \_\_\_\_\_  
 Orchiectomy, date: \_\_\_\_\_ Side: right / left LVI: yes/no  
 Date definitive staging: \_\_\_\_\_  
 Recurrence date: \_\_\_\_\_ fill out new form and switch FU

**TUMOR MARKERS SHOULD BE CHECKED EVERY 2 MONTHS YEAR 1 FOR PATIENTS WITH LVI+ MANAGED BY SURVEILLANCE**

Control type **B**: Patient contact, AFP,  $\beta$ -hCG, LDH, S-creatinine, **MRI of the retroperitoneum/** (abdominopelvic CT).  
 Control type **C**: Like B with addition of clinical examination, testosterone, SHBG, LH, FSH.  
 Control type **TM**: Tumour markers, AFP,  $\beta$ -hCG and LDH (*List the patient for a telephone appointment*).

Scrotal ultrasound when clinically indicated. Metabolic screening (lipids, fasting glucose, HbA1c), and blood pressure at 1- and 5-year visit. Inform Swedish patients at 1- and 5- year visit that a quality of life questionnaire will be sent out from RCC Syd, Sweden.

### Months from end of treatment:

	<b>TM</b>	<b>B</b>	<b>TM</b>	<b>C</b>	
<b>0</b>	<b>3</b>	<b>6</b>	<b>9</b>	<b>12</b>	<b>Follow-up year 1</b>
	<b>TM</b>	<b>B</b>	<b>TM</b>	<b>B</b>	
<b>12</b>	<b>15</b>	<b>18</b>	<b>21</b>	<b>24</b>	<b>Follow-up year 2</b>
		<b>TM</b>		<b>C</b>	
<b>24</b>		<b>30</b>		<b>36</b>	<b>Follow-up year 3</b>
		<b>TM</b>		<b>B</b>	
<b>36</b>		<b>42</b>		<b>48</b>	<b>Follow-up year 4</b>
		<b>TM</b>		<b>C</b>	
<b>48</b>		<b>54</b>		<b>60</b>	<b>Follow-up year 5</b>

**Postpubertal teratoma: No TM check-up month 3, 9, 15, 21**

**Patient care plan to be given to the patient at termination of follow-up**